Skye Biologics

Skye Biologics is a vertically integrated, private biotechnology company pioneering regenerative therapies based on its proprietary extracellular matrix (ECM) preservation technology. It currently commercializes a range of tissue allograft products for advanced wound care, surgical, and ocular applications through its sister tissue bank, while actively developing a clinical pipeline aimed at repairing musculoskeletal injuries and degenerative conditions. The company targets a massive market opportunity, aiming to address a $100+ billion healthcare spend by providing biologics that enhance healing, reduce complications, and lower long-term treatment costs. With a foundation in human placental tissue processing, Skye seeks to 'hack' the healing loop to restore tissue function across multiple high-need specialties.

Proprietary extracellular matrix (ECM) preservation technology (HydraTek®/BioAware®) for processing human placental tissues to create bioactive allografts that support tissue repair and regeneration.

Skye operates in the competitive regenerative medicine space, facing competition from large medtech companies (e.g., Integra LifeSciences, Smith & Nephew) in wound care allografts and from numerous biotechs developing orthobiologics and cell therapies for musculoskeletal repair. Its differentiation is its proprietary ECM preservation technology and vertical integration from tissue bank to clinic.